

# Adherence Labeling: Understanding the Origins, Limitations, and Ethical Challenges of “Diagnosing” Nonadherence

Sourik Beltrán, MD, MBE<sup>1,2</sup>

Peter F. Cronholm, MD, MSCE<sup>3</sup>

Stephen J. Bartels, MD, MS<sup>2</sup>

<sup>1</sup>Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

<sup>2</sup>The Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts

<sup>3</sup>Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, Pennsylvania

## ABSTRACT

Promoting adherence to medical recommendations remains one of the oldest yet most persistent challenges of modern clinical practice. Although increasingly sympathetic to structural forces that affect health behavior, standard models frequently conceptualize nonadherence as a phenomenon of patient behavior, a self-evident quality belonging to patients that is responsible for a myriad of undesired outcomes. We contend, however, that this approach not only fails to consider the role of the clinician in the concept's origins in clinical encounters, but also has facilitated the use of adherence terms (eg, nonadherent, noncompliant, treatment resistant) as pejorative social labels to the detriment of the physician-patient relationship. Used without care, such terminology can alter the meaning assigned to patients' behaviors so that structural barriers to care such as poverty and systemic racism are reframed as problems of poor attitude or effort. This article explores the functions of adherence terms as social labels by reviewing their underlying logic in clinical settings and outlining pitfalls in the pathologization of nonadherence in research and practice. We propose the concept of adherence labeling—the assessment, classification, and dissemination of clinicians' perceptions of patients' adherence through social labels—as an alternative model to understand how adherence terms may inadvertently obstruct the care of marginalized patients.

*Ann Fam Med* 2025;23:255-261. <https://doi.org/10.1370/afm.240358>

## INTRODUCTION

A Black woman aged 50 years with insulin-dependent diabetes experiences gaps in insurance related to unstable employment. During this period, she halves her insulin dose as a self-rationing strategy. Months later, she presents to her primary care clinic, where she is found to have progressive diabetic neuropathy and hyperglycemia. Her physician, influenced in part by implicit assumptions about race and individual responsibility, documents “poorly controlled diabetes due to nonadherence.” This description is viewed by other clinicians who draw similar conclusions about her willingness to participate in care. These feelings toward the patient affect her experiences in the clinic, leading her to feel alienated from both her physician and health care in general. What went wrong?

Encouraging adherence to treatment remains one of medicine's oldest and most persistent challenges.<sup>1,2</sup> Unfortunately, stigma has often accompanied descriptions of “nonadherent” patients with many scholars raising concern that such terms undermine patients' autonomy and blame them for poor health outcomes.<sup>3-9</sup> Although substantial effort has gone toward studying adherence as a behavior,<sup>10-12</sup> much less has been written about adherence as a label—that is, how the term adherence and its derivatives assign meaning to patients' behaviors. Several questions in this area remain unresolved. For example, how do such terms arise in clinical settings? How can nonadherence transform from something a patient *does* (nonadherent behavior) into something they *are* (a nonadherent patient)? Finally, what alternative (if any) could more appropriately capture this consequential clinical phenomenon?

Although labels may be a necessary part of clinical reasoning and practice, we argue that adherence terminology poses a unique risk to the care of socially vulnerable patients, for whom the stigma of terms such as nonadherent may outweigh their therapeutic promise. Here we lay conceptual groundwork necessary to understand how adherence labels can produce unintended harm among marginalized patients. To do this, we outline the logical underpinnings of adherence terminology

Conflicts of interest: authors report none.

## CORRESPONDING AUTHOR

Sourik Beltrán  
Beth Israel Deaconess Medical Center  
330 Brookline Ave, W/Space 2  
Boston, MA 02215  
[SBELTRAN@bidmc.harvard.edu](mailto:SBELTRAN@bidmc.harvard.edu)

and propose a new model for understanding the impact of these terms on clinical care that we call adherence labeling: the categorization of patients based on their perceived alignment with medical recommendations.

## UNDERSTANDING ADHERENCE DOCUMENTATION

Although adherence has undergone extensive elaboration in today's literature, most interpretations focus on patients' behaviors; however, we believe that this approach does not adequately recognize the role of the clinician in the concept's origins. In this section, we explore adherence as an idea emerging from the clinical encounter rather than as a self-evident fact pertaining to patients.

In an idealized setting, at least 3 conditions are necessary for adherence terminology to be used. First, there must be a recommendation that a clinician either provides or endorses. Second, a clinician must determine—by observation, self-reported or collateral history, prior documentation, or inference—whether a patient meets a particular standard with respect to that recommendation. Third, that clinician must decide whether their assessment of the patient's adherence warrants explicit mention.

The process above illustrates several features not captured in standard adherence models. First, we see the meaning applied to patients' attitudes and behaviors is of central importance—adherence both depends on and informs how clinicians perceive patients. Second, adherence terminology can be observed to operate along a categorical binary. Even if one chooses to describe patients as having varying degrees of adherence, its relevance as a clinical problem—epitomized by the term nonadherence itself—implies a threshold below which lesser degrees of adherence should be considered problematic. Lastly, we see determinations of adherence not only depend on clinicians' assessments but, in fact, take place exclusively on the clinician's side. That is, patients may disclose or directly exhibit behavior that objectively contrasts with a clinician's recommendations, but it is ultimately the clinician who decides whether such behaviors warrant the explicit use of adherence terms. Taken together, the construction of adherence—or the emergence of concepts such as nonadherence or a nonadherent patient in a clinical encounter—resembles that of a diagnosis: these terms arise as a means to categorize patients based on the observations and judgments of a clinician.

## NONADHERENCE AS A DIAGNOSIS

Although nonadherence is not routinely discussed as a diagnosis, its tendency to be treated as one can be widely observed. Scholars have made repeated attempts to establish diagnostic criteria for nonadherence.<sup>10,13</sup> Epidemiologically, adherence is studied under the same risk model applied to standard medical conditions whereby nonadherence is conceived as a risk factor

for various clinical outcomes.<sup>14</sup> Conversely, scholars have sought to identify measurable risk factors for nonadherence,<sup>15</sup> some even attempting to pinpoint a genetic basis.<sup>16-19</sup>

In clinical practice, nonadherence is frequently mentioned in case presentations and problem lists alongside other diagnoses.<sup>20-25</sup> This practice is facilitated by the inclusion of non-compliance as a billable diagnosis in the *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Clinical Modification* (ICD-10-CM).<sup>26</sup> Practice guidelines instruct clinicians to be vigilant in recognizing nonadherence.<sup>10</sup> Explicit references to the role of clinicians "diagnosing" nonadherence are common.<sup>27-29</sup>

Short of being formally classified as a disease, nonadherence has been subject to nearly every major biomedical tool from risk models and outcomes measurements to genetic studies. This observation highlights another feature of adherence terminology: the concept of adherence relies on the pathologization of nonadherence. That is, the emergence of adherence as a desired clinical outcome has led to the framing of its opposite—nonadherence—as pathological.

There are at least 2 problems with pathologizing nonadherence. The first problem is that doing so carries a risky assumption: that it is normal for patients to adhere. Although there is no doubt nonadherence can cause harm, it is also known that health behaviors—outside of medical conditions that limit executive function (eg, psychiatric illness, dementia)—are frequently, if not exclusively, rational.<sup>5</sup> Behaviors characterized as nonadherent may represent a wide range of contextually appropriate decisions drawing from health-belief models, cultural or religious views, and experiences with poverty and systemic racism.<sup>30</sup> Systemic racism in particular may constrain patients' self-management behaviors while also driving medical mistrust.<sup>31</sup> Framing nonadherence as pathological thus creates a pathway for patients' social, cultural, and structural contexts to be obscured or, at worst, reframed as problems of insufficient effort.

The second problem with pathologizing nonadherence lies in its definition. In psychiatric nosology, behavioral diagnoses require particularly rigorous definition to reduce the risk of stigmatizing normal behavior.<sup>32</sup> Despite decades of attempts, scholars have struggled to generate a consistent, operational definition of nonadherence that establishes exactly when a patient's level of adherence should be considered problematic. Often, cutoffs are proposed for objective markers such as the medication possession ratio<sup>33</sup>; however, such metrics simply reinforce the concept of adherence as a categorical binary. Even among measures developed to capture varying degrees of adherence,<sup>12</sup> such tools' clinical applicability still relies on the development of cutoffs to serve as clinical standards.<sup>34</sup> Further, despite validation in the adherence literature, many such tools have rarely been adopted into clinical practice.<sup>12,35</sup>

As it stands, there are no widely accepted criteria for nonadherence. This raises an important question: how are clinicians deciding who should receive a diagnosis of

nonadherence? As any clinician can attest, the decision is left to the individual. This situation constitutes what we are calling the subjective dependence of adherence terminology—that absent an objective standard, determinations of adherence may depend disproportionately on clinicians' subjective assessments.

It has been shown in health equity literature that clinicians' attitudes toward patients depend on factors such as personal views, demographics, and clinician-patient identity concordance.<sup>36-40</sup> Several studies have demonstrated a similar effect in perceptions of adherence. Clinicians are often inaccurate in their judgments of patients' adherence when compared with objective measures.<sup>41,42</sup> One qualitative meta-analysis by Brundisini et al<sup>43</sup> found marked variability between clinicians' understanding of their patients' adherence. Similarly, van Ryn and Burke,<sup>44</sup> Bogart et al,<sup>45</sup> Lutfey and Ketcham,<sup>46</sup> and Huizinga et al<sup>47</sup> found disparities in clinicians' perceptions of adherence, with Black, obese, and poorer patients more often viewed as less adherent. Two additional studies revealed disproportionate application of the ICD-10 code for noncompliance among Black and poorer diabetic patients despite well-controlled glycemic markers.<sup>24,25</sup> Although research in this area is lacking, these findings support the hypothesis that clinicians rely on subjective assessments to determine patients' adherence, even when contradicted by objective data.<sup>24,25</sup>

Nonadherence may resemble a diagnosis in practice, but it demonstrates at least 2 qualities that distinguish it from a true medical condition. First, nonadherence, lacking a single unifying biopathological mechanism, represents primarily social rather than biologic information. Second, nonadherence is not routinely diagnosed by objective criteria and thus may be vulnerable to subjectivity and bias.

## NONADHERENCE AS A LABEL

In sociology, a label is a term that identifies a person based on observable qualities such as racial phenotype, class status, or behavior. Social labeling describes how actions considered disruptive to society undergo a process of public identification resulting in often pejorative terms.<sup>48</sup> Examples include terms related to mental illness, immigration status, or sexual practices.<sup>49-51</sup> By definition, social labels arise from a society's reaction to certain behaviors—this reaction both produces these social categories and assigns them meaning. Social labels thus do not indicate a behavior is inherently problematic or immoral but instead reflect a particular dominant social value.<sup>52,53</sup>

It is a well-established value that patients ought to follow physicians' recommendations.<sup>54</sup> Throughout history, patients who have not followed medical recommendations have been considered ignorant, dangerous, or even criminal.<sup>3,4</sup> Today, health care professionals continue to express frustration regarding nonadherent patients.<sup>55</sup> Although "noncompliant," "nonadherent," and similar concepts have proven useful in the

study of patients' health behaviors, our current models fail to capture the role of these terms as social labels. We therefore propose the idea of adherence labeling. We define adherence labeling as the assessment, classification, and dissemination of clinicians' perceptions of patients' adherence through the use of social constructs such as "compliance" or any of its contemporary substitutes (eg, adherence, concordance, engagement).

At its foundation, adherence labeling involves categorization. Through it, patients are sorted as adherent or nonadherent at a clinician's discretion. For patients to be labeled adherent or nonadherent, a clinician must not only perceive a patient's level of adherence but also decide to name and document it; thus, beyond categorization, adherence labeling is a process of knowledge production—it allows clinicians' subjective assessments of patients to become codified as legitimate clinical data.


Use of the term nonadherence allows consolidation of a wide variety of behaviors under a single concept. If a patient struggles to take medication because of structural factors such as poverty or racism and is labeled nonadherent, there is no guarantee an explanation of the specific driver of that patient's behavior will be made evident to subsequent clinicians. Instead, a patient may be incorrectly assumed to be defiant or careless rather than a victim of structural inequity. Adherence labeling therefore not only generates information about patients, but also has the potential to modify the meaning of patients' behaviors.

We may further imagine that nonadherence can be assigned to certain patients because of implicit biases. Once such a label is given to a patient, the biased origins of the term are likely to become lost. Instead, the label of nonadherence may be interpreted as a clinical fact belonging to the patient rather than to the clinician. To this end, adherence labeling also functions as a process of concealment so that potential prejudice involved in decisions to label patients may be hidden beneath the label itself.

## CASE DISCUSSION: THE "NONADHERENT" DIABETIC PATIENT

Returning to the case, we can observe that our patient was affected by racism through 2 interrelated mechanisms converging at her "nonadherence": structural racism limiting access to therapy and interpersonal racism driving adherence labeling in her records. Not only does the patient's unstable insurance lead to several negative health effects, but through adherence labeling, these outcomes are reimagined as evidence of her lack of engagement. Additionally, being labeled nonadherent led to worse care experiences that alienated the patient. This process itself may drive treatment hesitancy, which, in turn, may be seen as further evidence of her nonadherence. Our general concept of this cycle is shown in [Figure 1](#). We use the term medically suboptimal to refer to behaviors that contrast with clinician recommendations but may draw from a competing logic or broader context.

**Figure 1. Flowchart Illustrating Cyclic Effects of Adherence Labeling in Reframing and Potentially Exacerbating Existing Barriers to Medical Care**



The meaning of this patient's behavior underwent several transformations. Her rational decision to reduce her insulin was reframed as poor self-management. The negative outcomes she experienced were characterized as expected consequences of her carelessness. Lastly, the implicit bias that helped give rise to the label was obscured. These processes were contrived not only in the use of "nonadherence" but through the related phrase "poorly controlled diabetes." We therefore note that adherence labeling may arise from any value statement applied to patients' self-management. In summary, the patient has experienced multiple layers of harm, the meaning of which has been thoroughly modified

by adherence terminology. Meanwhile, her social context—poverty, underinsurance, experiences of bias—has been hidden behind the sterile objectivity of the nonadherence label.

Notably, the case also highlights several areas of potential mitigation. Intentional inquiry could have elicited the rationale behind the patient's behavior. Further, an awareness of stigma could have allowed the clinician to avoid unnecessary labeling and instead describe the patient's behavior and its logic. Finally, these changes could have led to the design of a more patient-centered care plan focused on addressing the patient's specific barriers to treatment.



## CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS

Few studies have investigated the clinical impact of adherence labeling. One reason may be that nonadherence is not commonly conceived as a label. Researchers may investigate behaviors labeled nonadherent, but rarely if ever examine how these labels come about or how they affect patient experiences and outcomes. Although limited, existing research on clinicians' attitudes toward nonadherent patients provides some insight.

It is known that clinicians may view nonadherent patients negatively.<sup>8,56,57</sup> Patients perceived as nonadherent may receive worse care including delays in necessary escalation of therapy for HIV and diabetes.<sup>58,59</sup> Patients seen as uncooperative may be expelled from clinics or receive inadequate mental health care.<sup>60,61</sup> Although system-level effects have not been explored, we might expect that labeling certain populations as nonadherent could impact decisions regarding resource allocation and program development. This influence would be particularly concerning considering the potential role of bias in individual adherence labeling. We suggest adherence labeling as a conceptual basis to investigate exactly which patients are being labeled nonadherent and how these terms affect both individual and macroscopic health care decisions. For example, vignette-based questionnaires could aim to measure the impact of adherence labels on clinical decisions. Additionally, studies could build on prior implicit bias literature to generate and test mitigation strategies for stigma associated with adherence terms.

Despite the potential harms of adherence labeling, we caution against the impulse to simply avoid adherence terms altogether. Rather, what is needed is a deeper understanding of the social and structural dynamics that underlie this labeling. For example, situating adherence labeling within incentive structures may help us understand the possible influence of outside pressures, such as concerns about liability that drive labeling as a form of defensive documentation. In addition, adherence labeling may be understood as drawing from the persistent cultural notion that patients should follow clinicians' recommendations without question, an assumption that may explain why "nonadherence" can provoke frustration and judgment. Considering these factors is critical to envisioning an alternative approach to adherence that reduces stigma and emphasizes a more holistic and more forgiving view of patient behavior.

The goal of adherence documentation should be to accurately as well as equitably identify patients who need additional support to improve their disease management. Strategies for reducing the harms of adherence labeling should therefore focus on reimagining adherence documentation in such a way that emphasizes patient-specific barriers to care. Rather than characterizing patients as negligent, we might conceive of a version of adherence documentation in which these terms prompt clinicians to nonjudgmentally investigate the drivers of patients' medically suboptimal

behaviors. Alternatively, choosing language that simply states patients' behaviors and their causes (eg, "low medication use due to underinsurance") may help to reduce stigma and bring needed attention to patients' modifiable social contexts.<sup>62</sup> As highlighted in the presented case, care plans could be designed around patient-specific barriers to treatment through the use of validated interventions such as intensive outpatient case management, simplified regimens, or the addressing of medical racism.<sup>11,63,64</sup> If clinicians can view terms such as nonadherence as opportunities to build a stronger therapeutic alliance with patients, especially with those already at the margins of our health care system, adherence terminology could possibly be leveraged to help close rather than exacerbate gaps in health equity. Clinicians should become more aware of the limitations and potential harms of adherence labeling in order to promote a more patient-centered, structurally informed approach to adherence.



[Read or post commentaries in response to this article.](#)

**Key words:** adherence; patient noncompliance; stigma; bias; bioethics; systemic racism; primary care issues: patient-centered care; social labels; physician-patient relations; motivation; barriers; health behavior; social marginalization; minority groups; vulnerable populations

Submitted July 26, 2024; submitted, revised, December 7, 2024; accepted January 20, 2025.

**Author contributions:** S.B. was primarily responsible for conceptualization and manuscript preparation. S.J.B. and P.F.C. oversaw the project and contributed to conceptualization and revision.

**Previous presentations:** Some of the content found in this article (including an earlier version of [Figure 1](#)) was presented in a poster session under the title "Who are we helping?—Ethical considerations in the documentation of patient refusal" at the Society of General Internal Medicine Annual Meeting; May 15-18, 2024; Boston, Massachusetts.

**Acknowledgments:** S.B. would like to acknowledge Deren Pulley of the Department of Humanities and Social Sciences at the University of California San Francisco for his thoughtful support and encouragement.

## References

1. Vrijens B, De Geest S, Hughes DA, et al; ABC Project Team. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol*. 2012;73(5):691-705. doi:[10.1111/j.1365-2125.2012.04167.x](https://doi.org/10.1111/j.1365-2125.2012.04167.x)
2. World Health Organization. *Adherence to Long-Term Therapies: Evidence for Action*. World Health Organization; 2003.
3. Lerner BH. From careless consumptives to recalcitrant patients: the historical construction of noncompliance. *Soc Sci Med*. 1997;45(9):1423-1431. doi:[10.1016/S0277-9536\(97\)00067-1](https://doi.org/10.1016/S0277-9536(97)00067-1)
4. Lerner BH, Gulick RM, Dubler NN. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. *Ann Intern Med*. 1998;129(7):573-578. doi:[10.7326/0003-4819-129-7-199810010-00012](https://doi.org/10.7326/0003-4819-129-7-199810010-00012)
5. Conrad P. The noncompliant patient in search of autonomy. *Hastings Cent Rep*. 1987;17(4):15-17. PMID: 3667244
6. Trostle JA. Medical compliance as an ideology. *Soc Sci Med*. 1988;27(12):1299-1308. doi:[10.1016/0277-9536\(88\)90194-3](https://doi.org/10.1016/0277-9536(88)90194-3)
7. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. *Arch Intern Med*. 1990;150(7):1377-1378. PMID: 2369237
8. Brunton S. I have never liked the term "compliance." *Clin Diabetes*. 2017;35(2):76-77. doi:[10.2337/cd17-0010](https://doi.org/10.2337/cd17-0010)

Disclaimer: Articles appearing in this format are peer-reviewed and accepted for publication, but may differ slightly from final published articles.

9. Skinner D, Franz B. From patients to populations: rhetorical considerations for a post-compliance medicine. *Rhetoric of Health & Medicine*. 2018;1(3-4):239-268. doi:[10.5744/rhm.2018.1013](https://doi.org/10.5744/rhm.2018.1013)
10. Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: a call for action. *Am Heart J*. 2011;162(3):412-424. doi:[10.1016/j.ahj.2011.06.007](https://doi.org/10.1016/j.ahj.2011.06.007)
11. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. *Ann Intern Med*. 2012;157(11):785-795. doi:[10.7326/0003-4819-157-11-201212040-00538](https://doi.org/10.7326/0003-4819-157-11-201212040-00538)
12. Lam WY, Fresco P. Medication adherence measures: an overview. *Biomed Res Int*. 2015;2015:217047. doi:[10.1155/2015/217047](https://doi.org/10.1155/2015/217047)
13. Tang KL, Quan H, Rabi DM. Measuring medication adherence in patients with incident hypertension: a retrospective cohort study. *BMC Health Serv Res*. 2017;17(1):135. doi:[10.1186/s12913-017-2073-y](https://doi.org/10.1186/s12913-017-2073-y)
14. Oates GR, Juarez LD, Hansen B, Kiefe CI, Shikany JM. Social risk factors for medication nonadherence: findings from the CARDIA study. *Am J Health Behav*. 2020;44(2):232-243. doi:[10.5993/AJHB.44.2.10](https://doi.org/10.5993/AJHB.44.2.10)
15. Van Alsten SC, Harris JK. Cost-related nonadherence and mortality in patients with chronic disease: a multiyear investigation, National Health Interview Survey, 2000-2014. *Prev Chronic Dis*. 2020;17:E151. doi:[10.5888/pcd17.200244](https://doi.org/10.5888/pcd17.200244)
16. Reach G. Is there an impatience genotype leading to non-adherence to long-term therapies? *Diabetologia*. 2010;53(8):1562-1567. doi:[10.1007/s00125-010-1755-3](https://doi.org/10.1007/s00125-010-1755-3)
17. McBride CM, Bryan AD, Bray MS, Swan GE, Green ED. Health behavior change: can genomics improve behavioral adherence? *Am J Public Health*. 2012;102(3):401-405. doi:[10.2105/AJPH.2011.300513](https://doi.org/10.2105/AJPH.2011.300513)
18. Seo I, Suh SI, Suh MH, Baek WK. Genome-wide association study of medication adherence in chronic diseases in the Korean population. *Genomics Inform*. 2014;12(3):121-126. doi:[10.5808/GI.2014.12.3.121](https://doi.org/10.5808/GI.2014.12.3.121)
19. Nakamura Y, Tamura T, Narita A, et al; J-MICC Research Group Consortium. A genome-wide association study on adherence to low-carbohydrate diets in Japanese. *Eur J Clin Nutr*. 2022;76(8):1103-1110. doi:[10.1038/s41430-022-01090-w](https://doi.org/10.1038/s41430-022-01090-w)
20. Keszthelyi S, Blasszauer B. Challenging non-compliance. *J Med Ethics*. 2003;29(4):257-259. doi:[10.1136/jme.29.4.257](https://doi.org/10.1136/jme.29.4.257)
21. Kubota S, Fukata S, Matsuzuka F, Kuma K, Miyauchi A. Successful management of a patient with pseudomalabsorption of levothyroxine. *Int J Psychiatry Med*. 2003;33(2):183-188. doi:[10.2190/OYWR-8DRV-HHP4-UE2E](https://doi.org/10.2190/OYWR-8DRV-HHP4-UE2E)
22. Luzzi V, Brunori M, Terranova S, et al. Difficult-to-treat OSAS: combined continuous positive airway pressure (CPAP) and mandibular advancement devices (MADs) therapy. A case report. *Cranio*. 2020;38(3):196-200. doi:[10.1080/08869634.2018.1496628](https://doi.org/10.1080/08869634.2018.1496628)
23. Mohanty K, Prasad MK, Gandhi S, Thirthalli J. Effect of nurse-led counseling on maintenance of healthy lifestyle among outpatients receiving antipsychotics: clinical case reports. *Indian J Psychol Med*. 2022;44(2):185-188. doi:[10.1177/025371762111021283](https://doi.org/10.1177/025371762111021283)
24. Beltrán S, Lett E, Cronholm PF. Nonadherence labeling in primary care: bias by race and insurance type for adults with type 2 diabetes. *Am J Prev Med*. 2019;57(5):652-658. doi:[10.1016/j.amepre.2019.06.005](https://doi.org/10.1016/j.amepre.2019.06.005)
25. Beltrán S, Arenas DJ, López-Hinojosa IJ, Tung EL, Cronholm PF. Associations of race, insurance, and zip code-level income with nonadherence diagnoses in primary and specialty diabetes care. *J Am Board Fam Med*. 2021;34(5):891-897. doi:[10.3122/jabfm.2021.05.200639](https://doi.org/10.3122/jabfm.2021.05.200639)
26. World Health Organization. *International Classification of Diseases. Tenth Revision, Clinical Modification (ICD-10-CM)*. ICD-10-CM Codes, Z00-Z99, Persons with potential health hazards related to family and personal history and certain conditions influencing health status Z77-Z99. World Health Organization. Published Oct 1, 2013. Accessed Jul 19, 2024. <https://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z77-Z99>
27. Ye S, Krupka DJ, Davidson KW. Diagnosing medication non-adherence in a patient with myocardial infarction. *Front Psychol*. 2012;3:267. doi:[10.3389/fpsyg.2012.00267](https://doi.org/10.3389/fpsyg.2012.00267)
28. Marcum ZA, Sevik MA, Handler SM. Medication nonadherence: a diagnosable and treatable medical condition. *JAMA*. 2013;309(20):2105-2106. doi:[10.1001/jama.2013.4638](https://doi.org/10.1001/jama.2013.4638)
29. Lane D, Lawson A, Burns A, et al; Endorsed by the European Society of Hypertension (ESH) Working Group on Cardiovascular Pharmacotherapy and Adherence. Nonadherence in hypertension: how to develop and implement chemical adherence testing. *Hypertension*. 2022;79(1):12-23. doi:[10.1161/HYPERTENSIONAHA.121.17596](https://doi.org/10.1161/HYPERTENSIONAHA.121.17596)
30. Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. *Syst Rev*. 2019;8(1):112. doi:[10.1186/s13643-019-1014-8](https://doi.org/10.1186/s13643-019-1014-8)
31. Bazargan M, Cobb S, Assari S. Discrimination and medical mistrust in a racially and ethnically diverse sample of California adults. *Ann Fam Med*. 2021;19(1):4-15. doi:[10.1370/afm.2632](https://doi.org/10.1370/afm.2632)
32. Wakefield JC. The concept of mental disorder. On the boundary between biological facts and social values. *Am Psychol*. 1992;47(3):373-388. doi:[10.1037//0003-066x.47.3.373](https://doi.org/10.1037//0003-066x.47.3.373)
33. Sattler EL, Lee JS, Perri M III. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. *Drugs Aging*. 2013;30(6):383-399. doi:[10.1007/s40266-013-0074-z](https://doi.org/10.1007/s40266-013-0074-z)
34. Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for medication adherence: a systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. *PLoS One*. 2017;12(11):e0187139. doi:[10.1371/journal.pone.0187139](https://doi.org/10.1371/journal.pone.0187139)
35. Kleinsinger F. The unmet challenge of medication nonadherence. *Perm J*. 2018;22:18-033. doi:[10.7812/TPP/18-033](https://doi.org/10.7812/TPP/18-033)
36. Haider AH, Schneider EB, Sriram N, et al. Unconscious race and social class bias among acute care surgical clinicians and clinical treatment decisions. *JAMA Surg*. 2015;150(5):457-464. doi:[10.1001/jamasurg.2014.4038](https://doi.org/10.1001/jamasurg.2014.4038)
37. McCarthy S. Gender inequality: unconscious and systematic bias remains a problem in emergency medicine. *Emerg Med Australas*. 2016;28(3):344-346. doi:[10.1111/1742-6723.12596](https://doi.org/10.1111/1742-6723.12596)
38. FitzGerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. *BMC Med Ethics*. 2017;18(1):19. doi:[10.1186/s12910-017-0179-8](https://doi.org/10.1186/s12910-017-0179-8)
39. Shen MJ, Peterson EB, Costas-Muñiz R, et al. The effects of race and racial concordance on patient-physician communication: a systematic review of the literature. *J Racial Ethn Health Disparities*. 2018;5(1):117-140. doi:[10.1007/s40615-017-0350-4](https://doi.org/10.1007/s40615-017-0350-4)
40. Dehon E, Weiss N, Jones J, Faulconer W, Hinton E, Sterling S. A systematic review of the impact of physician implicit racial bias on clinical decision making. *Acad Emerg Med*. 2017;24(8):895-904. doi:[10.1111/acem.13214](https://doi.org/10.1111/acem.13214)
41. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? *J Gen Intern Med*. 2002;17(1):1-11. doi:[10.1046/j.1525-1497.2002.09004.x](https://doi.org/10.1046/j.1525-1497.2002.09004.x)
42. Winters A, Esse T, Bhansali A, Serna O, Mhatre S, Sansgiry S. Physician perception of patient medication adherence in a cohort of Medicare Advantage plans in Texas. *J Manag Care Spec Pharm*. 2016;22(3):305-312. doi:[10.18553/jmcp.2016.22.3.305](https://doi.org/10.18553/jmcp.2016.22.3.305)
43. Brundisini F, Vanstone M, Hulan D, DeJean D, Giacomini M. Type 2 diabetes patients' and providers' differing perspectives on medication nonadherence: a qualitative meta-synthesis. *BMC Health Serv Res*. 2015;15(1):516. doi:[10.1186/s12913-015-1174-8](https://doi.org/10.1186/s12913-015-1174-8)
44. van Ryn M, Burke J. The effect of patient race and socio-economic status on physicians' perceptions of patients. *Soc Sci Med*. 2000;50(6):813-828. doi:[10.1016/s0277-9536\(99\)00338-x](https://doi.org/10.1016/s0277-9536(99)00338-x)
45. Bogart LM, Catz SL, Kelly JA, Benotsch EG. Factors influencing physicians' judgments of adherence and treatment decisions for patients with HIV disease. *Med Decis Making*. 2001;21(1):28-36. doi:[10.1177/0272989X0102100104](https://doi.org/10.1177/0272989X0102100104)
46. Lutfey KE, Ketcham JD. Patient and provider assessments of adherence and the sources of disparities: evidence from diabetes care. *Health Serv Res*. 2005;40(6 Pt 1):1803-1817. doi:[10.1111/j.1475-6773.2005.00433.x](https://doi.org/10.1111/j.1475-6773.2005.00433.x)
47. Huizinga MM, Bleich SN, Beach MC, Clark JM, Cooper LA. Disparity in physician perception of patients' adherence to medications by obesity status. *Obesity (Silver Spring)*. 2010;18(10):1932-1937. doi:[10.1038/oby.2010.35](https://doi.org/10.1038/oby.2010.35)
48. Barmaki R. On the origin of "Labeling" theory in criminology: Frank Tannenbaum and the Chicago School of Sociology. *Dev Behav*. 2019;40(2):256-271. doi:[10.1080/01639625.2017.1420491](https://doi.org/10.1080/01639625.2017.1420491)

49. Goffman E. *Stigma: Notes on the Management of Spoiled Identity*. Simon & Schuster; 1986.
50. Bustamante JA. The “wetback” as deviant: an application of labeling theory. *Am J Sociol*. 1972;77(4):706-718. Accessed Feb 12, 2025. <https://www.jstor.org/stable/2776755>
51. Stein A, Plummer K. I can’t even think straight: queer theory and the missing sexual revolution in sociology. *Social Theory*. 1994;12(2):178-187. doi: [10.2307/201863](https://doi.org/10.2307/201863)
52. Lemert EM. *Social Pathology: A Systematic Approach to the Theory of Sociopathic Behavior*. McGraw-Hill; 1951.
53. Lemert EM. Beyond Mead: the societal reactions to deviance. *Soc Probl*. 1974; 21(4):457-468. doi: [10.2307/799985](https://doi.org/10.2307/799985)
54. Kelly MP, May D. Good and bad patients: a review of the literature and a theoretical critique. *J Adv Nurs*. 1982;7(2):147-156. doi: [10.1111/j.1365-2648.1982.tb00222.x](https://doi.org/10.1111/j.1365-2648.1982.tb00222.x)
55. Young JB, Cordova JC. The noncompliant patient. *Methodist Debaquey Cardiovasc J*. 2022;18(5):81-84. doi: [10.14797/mdcvj.1166](https://doi.org/10.14797/mdcvj.1166)
56. Groves JE. Taking care of the hateful patient. *N Engl J Med*. 1978;298(16):883-887. doi: [10.1056/NEJM197804202981605](https://doi.org/10.1056/NEJM197804202981605)
57. Gunderman R. Illness as failure. Blaming patients. *Hastings Cent Rep*. 2000; 30(4):7-11. PMID: 10971886
58. el-Kebbi IM, Ziemer DC, Gallina DL, Dunbar V, Phillips LS. Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols. *Diabetes Care*. 1999;22(10):1617-1620. doi: [10.2337/diacare.22.10.1617](https://doi.org/10.2337/diacare.22.10.1617)
59. Wong MD, Cunningham WE, Shapiro MF, et al; HCSUS Consortium. Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients. *J Gen Intern Med*. 2004;19(4):366-374. doi: [10.1111/j.1525-1497.2004.30429.x](https://doi.org/10.1111/j.1525-1497.2004.30429.x)
60. Volk ML, Lieber SR, Kim SY, Ubel PA, Schneider CE. Contracts with patients in clinical practice. *Lancet*. 2012;379(9810):7-9. doi: [10.1016/S0140-6736\(11\)60170-0](https://doi.org/10.1016/S0140-6736(11)60170-0)
61. Fadus MC, Ginsburg KR, Sobowale K, et al. Unconscious bias and the diagnosis of disruptive behavior disorders and ADHD in African American and Hispanic youth. *Acad Psychiatry*. 2020;44(1):95-102. doi: [10.1007/s40596-019-01127-6](https://doi.org/10.1007/s40596-019-01127-6)
62. Healy M, Richard A, Kidia K. How to reduce stigma and bias in clinical communication: a narrative review. *J Gen Intern Med*. 2022;37(10):2533-2540. doi: [10.1007/s11606-022-07609-y](https://doi.org/10.1007/s11606-022-07609-y)
63. Torres-Robles A, Wiecek E, Tonin FS, Benrimoj SI, Fernandez-Llimos F, Garcia-Cardenas V. Comparison of interventions to improve long-term medication adherence across different clinical conditions: a systematic review with network meta-analysis. *Front Pharmacol*. 2018;9:1454. doi: [10.3389/fphar.2018.01454](https://doi.org/10.3389/fphar.2018.01454)
64. Conn VS, Ruppar TM, Enriquez M, Cooper P. Medication adherence interventions that target subjects with adherence problems: Systematic review and meta-analysis. *Res Social Adm Pharm*. 2016;12(2):218-246. doi: [10.1016/j.sapharm.2015.06.001](https://doi.org/10.1016/j.sapharm.2015.06.001)